Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Buy" by Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has been assigned an average rating of "Buy" from the six analysts that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have covered the stock in the last year is $30.50.

Several analysts have commented on TYRA shares. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Tuesday, February 18th. UBS Group began coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price for the company.

Tyra Biosciences Stock Performance

NASDAQ:TYRA traded down $0.07 during trading hours on Friday, reaching $10.24. The company's stock had a trading volume of 116,978 shares, compared to its average volume of 229,545. The stock has a 50 day moving average price of $12.85 and a two-hundred day moving average price of $16.54. The company has a market capitalization of $518.17 million, a P/E ratio of -6.36 and a beta of 1.09. Tyra Biosciences has a 12 month low of $9.93 and a 12 month high of $29.60.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the transaction, the director now directly owns 447,857 shares in the company, valued at $7,295,590.53. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 21,998 shares of company stock worth $344,818 over the last 90 days. 15.40% of the stock is currently owned by company insiders.

Remove Ads

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new stake in shares of Tyra Biosciences in the third quarter valued at about $491,000. Jennison Associates LLC lifted its stake in Tyra Biosciences by 5.9% in the 3rd quarter. Jennison Associates LLC now owns 158,187 shares of the company's stock valued at $3,719,000 after buying an additional 8,837 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Tyra Biosciences by 2.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company's stock worth $4,085,000 after buying an additional 3,792 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Tyra Biosciences during the third quarter valued at approximately $333,000. Finally, FMR LLC lifted its position in shares of Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company's stock valued at $79,296,000 after acquiring an additional 26,187 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.